105 related articles for article (PubMed ID: 8571742)
1. [Detection of minimal residual disease in acute leukemias by immunophenotyping of bone marrow cells].
Deptała A; Widzyńska I; Kuratowska Z
Acta Haematol Pol; 1995; 26(4):403-11. PubMed ID: 8571742
[TBL] [Abstract][Full Text] [Related]
2. [Clinical significance and prognostic detection of minimal residual disease in acute leukemias].
Deptała A; Widzyńska I; Kuratowska Z
Acta Haematol Pol; 1995; 26(4):413-20. PubMed ID: 8571743
[TBL] [Abstract][Full Text] [Related]
3. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection.
DiGiuseppe JA; Fuller SG; Borowitz MJ
Cytometry B Clin Cytom; 2009 Mar; 76(2):150-5. PubMed ID: 18831072
[TBL] [Abstract][Full Text] [Related]
5. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
[TBL] [Abstract][Full Text] [Related]
6. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia.
Veltroni M; De Zen L; Sanzari MC; Maglia O; Dworzak MN; Ratei R; Biondi A; Basso G; Gaipa G;
Haematologica; 2003 Nov; 88(11):1245-52. PubMed ID: 14607753
[TBL] [Abstract][Full Text] [Related]
7. [Immunophenotyping in acute leukemia: detection of minimal residual disease].
Pálóczi K; Nahajevszky S; Jakab K; Regéczy N; Gopcsa L; László E; Földi J
Orv Hetil; 2000 Nov; 141(46):2487-92. PubMed ID: 11126681
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
Ciudad J; Orfao A; Vidriales B; Macedo A; Martínez A; González M; López-Berges MC; Valverde B; San Miguel JF
Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
[TBL] [Abstract][Full Text] [Related]
9. Leukemia-associated phenotypes: their characteristics and incidence in acute leukemia.
Babusíková O; Glasová M; Koníková E; Kusenda J
Neoplasma; 1996; 43(6):367-72. PubMed ID: 8996560
[TBL] [Abstract][Full Text] [Related]
10. Expression of CD10, CD19 and CD34 markers in bone marrow samples of children with precursor B-cell acute lymphoblastic leukemia in clinical and hematological remission.
Cáp J; Babusíková O; Kaiserová E; Jamárik M
Neoplasma; 1998; 45(4):231-6. PubMed ID: 9890666
[TBL] [Abstract][Full Text] [Related]
11. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
[TBL] [Abstract][Full Text] [Related]
12. [Detection of minimal residual disease in patients with acute myeloid leukemia].
Gal'tseva IV; Savchenko VG; Kulikov SM; Parovichnikova EN; Miterev GIu; Maslova ER; Isaev VG
Ter Arkh; 2003; 75(7):8-14. PubMed ID: 12934474
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L
Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometric determination of leukemia-associated marker combinations for the study of minimal residual disease.
Babusíková O; Glasová M; Kusenda J; Koníková E; Mésárosová A
Neoplasma; 1994; 41(6):305-13. PubMed ID: 7870213
[TBL] [Abstract][Full Text] [Related]
15. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
Zelezníková T; Babusíková O
Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
[TBL] [Abstract][Full Text] [Related]
16. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease testing in acute leukemia by flow cytometry immunophenotyping: prognostic significance.
Ruiz-Argüelles GJ; Fernández-Lara D; Estrada-Gómez R; Manzano C; Ruiz-Delgado GJ; Pérez-Romano B; Ruiz-Argüelles A
Lab Hematol; 2007; 13(1):22-6. PubMed ID: 17353179
[TBL] [Abstract][Full Text] [Related]
18. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.
Qin Y; Zhu H; Jiang B; Li J; Lu X; Li L; Ruan G; Liu Y; Chen S; Huang X
Leuk Res; 2009 Mar; 33(3):384-90. PubMed ID: 18950857
[TBL] [Abstract][Full Text] [Related]
19. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
[TBL] [Abstract][Full Text] [Related]
20. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry.
Al-Mawali A; Gillis D; Hissaria P; Lewis I
Am J Clin Pathol; 2008 Jun; 129(6):934-45. PubMed ID: 18480011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
